Screener
Iovance Biotherapeutics, Inc. IOVA PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Inventory | 55,590 | 51,678 |
| Prepaid expenses and other assets | 8,874 | 11,583 |
| Total Current Assets | 464,257 | 442,689 |
| Property and equipment, net | 131,464 | 131,112 |
| Intangible assets, net | 263,894 | 279,324 |
| Operating lease right-of-use assets | 43,480 | 45,899 |
| Restricted cash | 6,005 | 5,980 |
| Long-term assets | 6,431 | 8,166 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s PP&E (net)?
- Iovance Biotherapeutics, Inc. (IOVA) reported PP&E (net) of $131.46M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s PP&E (net) changed year-over-year?
- Iovance Biotherapeutics, Inc.'s PP&E (net) increased by 7.3% year-over-year, from $122.47M to $131.46M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s PP&E (net) has grown at a 17.3% compound annual growth rate (CAGR), from $59.16M to $131.11M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Iovance Biotherapeutics, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude